Who are MCI-186 in open label phase's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Edaravone Dexborneol, Radicava ORS, Compound Edaravone Injection, N-Acetylcysteine Amide, MCI-186, Edaravone Dexborneol Sublingual Tablets.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mci-186-in-open-label-phase.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

MCI-186 in open label phase — Competitive Intelligence Brief

MCI-186 in open label phase (MCI-186 in open label phase) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Free radical scavenger. Area: Neuroprotection.

phase 3 Free radical scavenger Neuroprotection Small molecule Live · refreshed every 30 min

Target snapshot

MCI-186 in open label phase (MCI-186 in open label phase) — Tanabe Pharma Corporation. MCI-186 is a free radical scavenger.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
MCI-186 in open label phase TARGET	MCI-186 in open label phase	Tanabe Pharma Corporation	phase 3	Free radical scavenger
Edaravone Dexborneol	Edaravone Dexborneol	First Affiliated Hospital, Sun Yat-Sen University	marketed	Free radical scavenger combination
Radicava ORS	Radicava ORS	Shanghai Auzone Biological Technology Co., Ltd.	marketed	Free radical scavenger; antioxidant	Free radicals (hydroxyl radicals); non-selective antioxidant mechanism
Compound Edaravone Injection	Compound Edaravone Injection	Jiangsu Simcere Pharmaceutical Co., Ltd.	phase 3	Free radical scavenger / Antioxidant	Hydroxyl radicals and reactive oxygen species
N-Acetylcysteine Amide	N-Acetylcysteine Amide	Nacuity Pharmaceuticals, Inc.	phase 3	Antioxidant / Free radical scavenger	Intracellular glutathione synthesis; free radicals / reactive oxygen species
MCI-186	MCI-186	Tanabe Pharma Corporation	phase 3	Free radical scavenger; antioxidant	Reactive oxygen species (ROS); hydroxyl radicals; peroxynitrite
Edaravone Dexborneol Sublingual Tablets	Edaravone Dexborneol Sublingual Tablets	Peking Union Medical College Hospital	phase 3	Free radical scavenger with permeation enhancer	Hydroxyl radicals and reactive oxygen species (ROS)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Free radical scavenger class)

Tanabe Pharma Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MCI-186 in open label phase — Competitive Intelligence Brief. https://druglandscape.com/ci/mci-186-in-open-label-phase. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab